PsychedelicNewsBreaks Archive - Page 47 of 65

MondayMay 10, 2021 10:07 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services for the development of novel pharmaceutical products, and the agreement outlines the collaboration between the two companies, as well as other clinical partners, will include medical writing, biostatistical analysis, data management and trial monitoring. The…

FridayMay 07, 2021 11:03 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized during the test. XPhyto's clinical partner for the project is Spitzweg Apotheke, a well-known pharmacy in Langen near Frankfurt, Germany, currently running a COVID-19 test center at a clinic, where it also provides special pharmacy…

FridayMay 07, 2021 9:28 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Present at Global Small Cap Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May 13, 2021, is designed to connect promising small cap companies with investors and traders. Drysdale’s presentation on Cybin is scheduled to begin at 3:55 p.m. ET. The presentation will be broadcast live; a replay will also be available for seven days following the conference. In addition to his Cybin presentation, Drysdale will also serve as a key member of a panel discussion focused on investing…

ThursdayMay 06, 2021 1:00 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss the company’s various lines of business, including its work to scale industrial production of pharmaceutical-grade psychedelics. “The psychedelic space is really exciting. This is absolutely the cutting edge of mental…

MondayMay 03, 2021 3:21 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits…

MondayMay 03, 2021 12:51 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Eyes Rapid Progress to Clinical Studies for Psychedelic Drug Candidates

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progression of two psychedelic drug candidates: CYB003 and CYB004. According to Cybin, the studies were completed in record time, in part due to close collaboration with the company’s partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Michael Palfreyman, Cybin’s chief R&D officer, in a…

MondayMay 03, 2021 11:07 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has provided a corporate update regarding its cannabis, functional mushroom and psilocybin business operations. The update notes that, in spite of COVID-19, its Pemberton, British Columbia facility is fully operational and in daily production. The company is focused on scalable entry into the U.S. market through a partnership with an Oregon-based, multistate operator (“MSO”). The company intends to produce its own branded products as well as white label products. In Canada, the company is ramping…

MondayMay 03, 2021 10:13 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp's clinical trial activities and will strengthen Tryp's capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials…

WednesdayApr 28, 2021 11:32 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Subsidiary Signs Tolling Agreement, Takes Delivery of CBD

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, announced that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has entered into a tolling agreement. The agreement outlines the extraction of 80–85% pure CBD distillate from an initial 500 kgs of hemp biomass, sourced from one of Pure Extracts’ preferred suppliers. The distillate has a CBD potency of over 10%. The announcement noted that the biomass has a specific particulate mill size and runs efficiently on PULL’s Vitalis R200 sub/super-critical CO2extraction system. The company…

MondayApr 26, 2021 1:55 pm

PsychedelicNewsBreaks – PsyBio Therapeutics Corp. (TSXV: PSYB) Expands Collaboration with Miami University to Expedite FDA IND Submission

PsyBio (TSXV: PSYB), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio. The amended agreement extends and expands the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper and Biomedical Engineering (the "Jones Lab") to include additional research efforts of the laboratory of Dr. Matthew McMurray in the Department of Psychology (the "McMurray Lab"), and to provide an additional US$1.5 million in funding until May 2023 to Miami University to support all such research.…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

PsychedelicNewsBreaks